

## PROVINCIAL FUNDING SUMMARY

Bevacizumab (Mvasi) for Metastatic Colorectal Cancer / Non-Small Cell Lung Cancer Biosimilar (pCODR 10158)

[Final Biosimilar Summary Dossier](#) Issued: January 14, 2019

This information is current as of May 1, 2020.

Note: Funding criteria as listed on the decision date. Please refer to the provincial drug programs for the most recent funding criteria and program eligibility.

PROVINCE	FUNDING STATUS	FUNDING DATE	FUNDING CRITERIA
BC	Funded	Nov 1, 2019	As per BC Cancer protocol.
AB	Under provincial consideration		
SK	Funded	Jan 27, 2020	As per SK Cancer protocol.
MB	Funded	Sep 23, 2019	As per MB Cancer protocol.
ON	Funded	Aug 19, 2019	As per ON Cancer protocol.
NS	Under provincial consideration		
NB	Not applicable		
NL	Under provincial consideration		
PEI	Under provincial consideration		

*Under provincial consideration* means that the province is reviewing pCODR's recommendation. This may include the province working with the drug manufacturer to reach an agreement for a drug product that both parties can accept, in particular in cases where the pCODR Expert Review Committee has recommended that the drug be funded only on the condition of cost-effectiveness being improved to an acceptable level. This may occur before or after the pan-Canadian Pharmaceutical Alliance negotiations. Please contact the specific provincial drug program and/or cancer agency in your province for information about the status of a given drug product.